Free Trial
NASDAQ:RARE

Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis

Ultragenyx Pharmaceutical logo
$39.19 -0.27 (-0.68%)
Closing price 07/3/2025 03:25 PM Eastern
Extended Trading
$39.19 0.00 (0.00%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE)

Key Stats

Today's Range
$39.02
$39.98
50-Day Range
$33.42
$39.46
52-Week Range
$29.59
$60.37
Volume
685,292 shs
Average Volume
838,182 shs
Market Capitalization
$3.71 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$87.00
Consensus Rating
Moderate Buy

Company Overview

Ultragenyx Pharmaceutical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
83rd Percentile Overall Score

RARE MarketRank™: 

Ultragenyx Pharmaceutical scored higher than 83% of companies evaluated by MarketBeat, and ranked 523rd out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ultragenyx Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Ultragenyx Pharmaceutical has only been the subject of 3 research reports in the past 90 days.

  • Read more about Ultragenyx Pharmaceutical's stock forecast and price target.
  • Earnings Growth

    Earnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($5.18) to ($3.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ultragenyx Pharmaceutical is -6.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ultragenyx Pharmaceutical is -6.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ultragenyx Pharmaceutical has a P/B Ratio of 14.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Ultragenyx Pharmaceutical's valuation and earnings.
  • Percentage of Shares Shorted

    6.81% of the float of Ultragenyx Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    Ultragenyx Pharmaceutical has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Ultragenyx Pharmaceutical has recently increased by 9.55%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Ultragenyx Pharmaceutical does not currently pay a dividend.

  • Dividend Growth

    Ultragenyx Pharmaceutical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.81% of the float of Ultragenyx Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    Ultragenyx Pharmaceutical has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Ultragenyx Pharmaceutical has recently increased by 9.55%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Ultragenyx Pharmaceutical has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Ultragenyx Pharmaceutical this week, compared to 8 articles on an average week.
  • Search Interest

    6 people have searched for RARE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $118,824.00 in company stock.

  • Percentage Held by Insiders

    Only 5.50% of the stock of Ultragenyx Pharmaceutical is held by insiders.

  • Percentage Held by Institutions

    97.67% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Ultragenyx Pharmaceutical's insider trading history.
Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

RARE Stock News Headlines

INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
See More Headlines

RARE Stock Analysis - Frequently Asked Questions

Ultragenyx Pharmaceutical's stock was trading at $42.07 on January 1st, 2025. Since then, RARE stock has decreased by 6.8% and is now trading at $39.19.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released its quarterly earnings results on Tuesday, May, 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing the consensus estimate of ($1.54) by $0.03. The business's revenue was up 28.0% compared to the same quarter last year.
Read the conference call transcript
.

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ultragenyx Pharmaceutical investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/06/2025
Today
7/03/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RARE
Employees
1,310
Year Founded
2010

Price Target and Rating

Average Stock Price Target
$87.00
High Stock Price Target
$136.00
Low Stock Price Target
$48.00
Potential Upside/Downside
+118.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
14 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$569.18 million
Pretax Margin
-92.62%

Debt

Sales & Book Value

Annual Sales
$560.23 million
Price / Cash Flow
N/A
Book Value
$2.76 per share
Price / Book
14.46

Miscellaneous

Free Float
89,342,000
Market Cap
$3.77 billion
Optionable
Optionable
Beta
0.26

Social Links

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:RARE) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners